Literature DB >> 7573273

Levels of hepatocyte growth factor in maternal serum and amniotic fluid.

N Horibe1, T Okamoto, A Itakura, T Nakanishi, T Suzuki, S Kazeto, Y Tomoda.   

Abstract

OBJECTIVE: The purpose of our study was to investigate hepatocyte growth factor levels in maternal serum and amniotic fluid during pregnancy. We also demonstrated production and secretion of hepatocyte growth factor by placenta and amnion at different stages of gestation. STUDY
DESIGN: Hepatocyte growth factor levels in maternal serum (n = 219), cord blood (n = 20), and amniotic fluid samples (n = 90) were measured by an enzyme-linked immunosorbent assay. The secretion of hepatocyte growth factor by placenta and amnion was evaluated by measuring the amount released into the culture supernatant.
RESULTS: Most hepatocyte growth factor levels in maternal serum were below the detection limit before 10 weeks of pregnancy. Levels increased significantly thereafter and continued to increase until term. On the other hand, levels in amniotic fluid were significantly higher between 20 and 29 weeks of gestation than after 30 weeks. Hepatocyte growth factor secretion from the placental tissue per weight seemed unchanged throughout pregnancy. Its secretion from amnion was, however, approximately 300 to 400-fold higher in the second trimester compared with that at term.
CONCLUSION: Both placenta and amnion produce and secrete hepatocyte growth factor, suggesting its role in fetal growth and the growth and differentiation of placenta.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573273     DOI: 10.1016/0002-9378(95)90370-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Fetal growth restriction and hepatocyte growth factor.

Authors:  D A Somerset; S C Afford; A J Strain; M D Kilby
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-11       Impact factor: 5.747

2.  Mechanisms in the adaptation of maternal β-cells during pregnancy.

Authors:  Sara Ernst; Cem Demirci; Shelley Valle; Silvia Velazquez-Garcia; Adolfo Garcia-Ocaña
Journal:  Diabetes Manag (Lond)       Date:  2011-03-01

3.  Ontogeny of hepatocyte growth factor (HGF) and its receptor (c-met) in human placenta: reduced HGF expression in intrauterine growth restriction.

Authors:  D A Somerset; X F Li; S Afford; A J Strain; A Ahmed; R K Sangha; M J Whittle; M D Kilby
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

4.  Loss of HGF/c-Met signaling in pancreatic β-cells leads to incomplete maternal β-cell adaptation and gestational diabetes mellitus.

Authors:  Cem Demirci; Sara Ernst; Juan C Alvarez-Perez; Taylor Rosa; Shelley Valle; Varsha Shridhar; Gabriella P Casinelli; Laura C Alonso; Rupangi C Vasavada; Adolfo García-Ocana
Journal:  Diabetes       Date:  2012-03-16       Impact factor: 9.461

5.  Colostrum and Mature Human Milk of Women from London, Moscow, and Verona: Determinants of Immune Composition.

Authors:  Daniel Munblit; Marina Treneva; Diego G Peroni; Silvia Colicino; LiYan Chow; Shobana Dissanayeke; Priya Abrol; Shreya Sheth; Alexander Pampura; Attilio L Boner; Donna T Geddes; Robert J Boyle; John O Warner
Journal:  Nutrients       Date:  2016-11-03       Impact factor: 5.717

6.  Hepatocyte growth factor/c-Met signaling is required for β-cell regeneration.

Authors:  Juan Carlos Alvarez-Perez; Sara Ernst; Cem Demirci; Gabriella P Casinelli; Jose Manuel D Mellado-Gil; Francisco Rausell-Palamos; Rupangi C Vasavada; Adolfo Garcia-Ocaña
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

7.  Circulating Levels of Bone and Inflammatory Markers in Gestational Diabetes Mellitus.

Authors:  Deirdre Cocks Eschler; Georgia Kulina; Adolfo Garcia-Ocana; Jiawen Li; Thomas Kraus; Carol J Levy
Journal:  Biores Open Access       Date:  2018-08-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.